Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.55 |
| ▸ | CMA1 | P23946 | 12/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7545974 | 0.92 | ACE (0.58) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL7545907 | 0.92 | ACE (0.58) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL8366751 | 0.90 | ACE (0.56) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL22961962 | 0.90 | ACE (0.72) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL8365074 | 0.90 | ACE (0.56) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL7148899 | 0.89 | ACE (0.63) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL7537159 | 0.89 | ACE (0.63) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL12658455 | 0.88 | KLK5 (0.69) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL7268512 | 0.88 | KLK5 (0.69) | ACEKLK5F2PRSS1CMA1 | |
| SCHEMBL28002546 | 0.88 | KLK5 (0.69) | ACEKLK5F2PRSS1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040150-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2021-02-11 | — | — | US | disclosed |
| WO-2021026492-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | Humanwell Pharmaceutical US (US) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040150-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | OPRK1, OPRL1, OPRD1 | ACE 1903/4885KLK5 964/4885F2 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.